Italfarmaco appoints Francesco Di Marco as CEO

9 October 2025

Privately-held Italian drugmaker Italfarmaco today announced that Dr Francesco Di Marco has been appointed as its chief executive (CEO), effective January 1, 2026.

Dr Di Marco brings over 25 years of experience in the biopharmaceutical industry through multiple executive leadership positions. He joined the company’s board of directors on October 1, 2025, as part of a structured leadership transition, succeeding Carlos Barallobre, the current CEO.

"Italfarmaco has built a broad global presence and a robust portfolio of products spanning hematology, oncology, cardiology, immunology, women’s health, and rare diseases. The company’s proven track record of improving people’s lives, together with its continued investment in research and development, reflects a culture of excellence and vision," said Dr Di Marco, adding: “I am especially inspired by our commitment to bringing givinostat (Duvyzat) treatment for Duchenne muscular dystrophy to patients worldwide – a testament to how innovation can change lives."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK